Attached files

file filename
EX-31 - 12JUN PRIN FIN 302 CERT - NMI Health, Inc.exhibit31_2june2012.htm
EX-32 - 12JUN PRIN EXEC 906 CERT - NMI Health, Inc.exhibit32_1june2012.htm
EX-32 - 12JUN PRIN FIN 906 CERT - NMI Health, Inc.exhibit32_2june2012.htm
EX-31 - 12JUN PRIN EXEC 302 CERT - NMI Health, Inc.exhibit31_1june2012.htm

 U.S. SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549


FORM 10-Q


[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934


For the Quarterly Period Ended: June 30, 2012


[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934


For the Transition Period From ________ to_________


Commission File No. 000-27421


NANO MASK, INC.

(Exact Name of Small Business Issuer as Specified in its Charter)



NEVADA

87-0561647

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)



50 West Liberty Street, Suite 880, Reno, NV

89501

(Address of principal executive offices)

(Zip code)


Issuer's telephone number, including area code: (209) 275-9270

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  (1) Yes [  ] No [X] (2) Yes [X] No [  ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes ¨    No ¨


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  ¨      Accelerated filer ¨         Non-accelerated filer    ¨       Smaller reporting company ý


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  ¨  Noý


State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date:


At August 14, 2012, there were outstanding 88,689,910 shares of the Registrant's Common Stock, $.001 par value.





PART I


FINANCIAL INFORMATION


Table of Contents

Page

 

 

Part I Financial Information

 

 

 

Item 1. Financial Statements

 

 

 

Balance Sheets (Unaudited) as of June 30, 2012 and December 31, 2011

3

 

 

Statements of Operations (Unaudited) for the three and six months ended June 30, 2012 and 2011

4

 

 

Statements of Cash Flows (Unaudited) for the six months ended June 30, 2012 and 2011

5

 

 

Notes to the Financial Statements (Unaudited)

6

 

 

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

8

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

   10

 

 

Item 4. Controls and Procedures

10

 

 

Part II  Other Information

 

 

 

Item 1. Legal Proceedings

11

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

11

 

 

Item 3. Defaults by the Company on its Senior Securities

12

 

 

Item 4. Submission of Matter to a Vote of Security Holders

12

 

 

Item 5. Other Information

12

 

 

Item 6. Exhibits

12

 

 

Signatures

12





2




NANO MASK, INC.

Balance Sheets

(Unaudited)

 

 

 

 

 

June 30,

 

December 31,

 

 

 

 

 

2012

 

2011

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

CURRENT ASSETS

 

 

 

 

 

 

Cash

 

 

 $                      -

 

 $                 61,504

 

Accounts receivable

 

 

-

 

422

 

Prepaid expenses and other

 

 

                 28,857

 

18,000

 

Inventory, net

 

 

              12,829

 

                  14,457

 

 

 

 

 

 

 

 

 

       Total current assets

 

 

 

              41,686

 

                  94,383

 

 

 

 

 

FIXED ASSETS

 

 

 

 

 

 

Equipment

 

 

5,673

 

5,673

 

Accumulated depreciation

 

 

 

                (823)

 

                   (490)

 

 

 

 

 

                4,850

 

                   5,183

 

 

 

 

 

 

 

 

 

      Total assets

 

 

 

$            46,536

 

$                 99,566

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

 

 

Customer advances

 

 

$               65,211

 

 $               150,517

 

Accounts payable

 

 

465,047

 

457,452

 

Accounts payable – related party

 

 

109,183

 

100,203

 

Accrued expenses

 

 

              386,920

 

                385,718

 

Notes payable

 

 

501,184

 

497,727

 

Note payable – related party

 

 

            25,000

 

                  25,000

 

      Total current liabilities

 

 

 

       1,552,545

 

             1,616,617

 

 

 

 

 

 

 

 

LONG-TERM DEBT

 

 

 

 

 

 

Note payable

 

 

 

             23,430

 

                  23,430

 

      Total liabilities

 

 

 

         1,575,975

 

            1,640,047

 

 

 

 

 

 

 

 

STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

Common stock, $.001 par, 100,000,000 shares authorized;88,689,910 and 80,249,698 shares

 

 

 

 

 

 

 

outstanding at June 30, 2012 and December 31, 2011, respectively

 

                  88,689

 

                  80,250

 

Additional paid-in capital

 

 

         21,415,828

 

           21,127,801

 

Accumulated deficit

 

 

   (23,033,956)

 

         (22,748,532)

 

      Total stockholders’ deficit

 

 

 

     (1,529,439)

 

           (1,540,481)

 

 

 

 

 

 

 

 

 

      Total liabilities and stockholders’ deficit

 

 

 

$            46,536

 

$                 99,566

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited financial statements.



3





NANO MASK INC.

Statements of Operations

(Unaudited)

 

 

 

 

 

For the Three Months Ended

 

For the Six Months Ended

 

June 30,

 

June 30,

 

2012

 

2011

 

2012

 

2011

 

 

 

 

 

 

 

 

NET SALES

$               81,388

 

$               25,533

 

$          299,738

 

$          25,683

 

 

 

 

 

 

 

 

COSTS AND EXPENSES

 

 

 

 

 

 

 

  Cost of sales

64,462

 

16,890

 

203,376

 

16,980

  Research and development

-

 

-

 

115

 

-

  Selling, general and administrative

     161,219

 

     257,088

 

          367,832

 

          396,791

 

     225,681

 

     273,978

 

           571,323

 

           413,771

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

  (144,293)

 

  (248,445)

 

    (271, 585)

 

    (388,088)

 

 

 

 

 

 

 

 

OTHER INCOME (EXPENSE)

 

 

 

 

 

 

 

  Gain on settlement of vendor liabilities and other

5,000

 

145,804

 

7,365

 

372,075

  Interest expense

         (10,581)

 

         (8,416)

 

            (21,204)

 

            (17,103)

 

(5,581)

 

137,388

 

         (13,839)

 

         354,972

 

 

 

 

 

 

 

 

NET LOSS

 $          (149,874)

 

 $          (111,057)

 

$         (285,424)

 

$         (33,116)

BASIC LOSS PER SHARE

 $                (0.00)

 

 $                (0.00)

 

$               (0.00)

 

 $             (0.00)

 

 

 

 

 

 

 

 

WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

88,417,676

 

66,275,014 

 

86,387,402

 

64,380,485 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited financial statements.























4






NANO MASK, INC.

Statements of Cash Flows

For the Six Months Ended June 30, 2012 and June 30, 2011

(Unaudited)

 

 

 

2012

 

2011

 

 

 

     

 

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

Net loss

$      (285,424)

 

$    (33,116)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

Depreciation

333

 

98

 

Common stock issued for company expenses incurred

-

 

12,170

 

Common stock issued for services

92,900

 

91,100

 

Gain on settlement of vendor liabilities

(7,365)

 

(372,075)

Changes in operating assets and liabilities:

 

 

 

 

Accounts receivable

422

 

(600)

 

Refund receivable

-

 

2,500

 

Inventory

1,628

 

(4,511)

 

Prepaid expenses

(10,857)

 

571

 

Customer advances

(85,306)

 

1,596

 

Accounts payable

199,733

 

275,111

 

Accrued expenses

             1,202

 

      (50,967)

 

 

Net cash used in operating activities

        (92,734)

 

       (78,123)

 

 

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

Proceeds from the issuance of common shares

25,000

 

-

 

Advances from related party

25,700

 

58,500

 

Repayment of advances from related party

(22,927)

 

(2,000)

 

Proceeds from issuance of related party short term note

-

 

25,000

 

Proceeds from the issuance of short-term note payable

5,149

 

-

 

Repayments of short-term note payable

            (1,692)

 

                    -

 

 

Net cash provided by financing activities

            31,230

 

          81,500

 

 

 

 

 

 

NET INCREASE (DECREASE) IN CASH

      (61,504)

 

      3,377

 

 

 

 

 

 

CASH AT BEGINNING OF PERIOD

             61,504

 

            2,810

 

 

 

 

 

 

CASH AT END OF PERIOD

$                   -

 

$          6,187

 

 

 

 

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

 

 

 

Cash paid for interest

$                   -

 

$                -

Cash paid for income taxes

$                   -

 

$                -

 

 

 

 

NON-CASH INVESTING AND FINANCING ACTIVITIES

 

 

 

Common stock issued for settlement of advances from related parties

$            8,703

 

$      103,300

Common stock issued for settlement of accounts payable and accrued liabilities

$        169,863

 

$      178,700

 

 

 

 

The accompanying notes are an integral part of these unaudited financial statements.



5



NANO MASK, INC.

Notes to the Financial Statements (Unaudited)

For the Six Months Ended June 30, 2012



NOTE 1 - BASIS OF PRESENTATION


The financial information included herein is unaudited and has been prepared consistent with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8, Rule 8.03 of Regulation S-K. Accordingly, these financial statements do not include all information required by generally accepted accounting principles for annual financial statements. These statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2011, from which the balance sheet information as of that date is derived. These interim financial statements contain all adjustments necessary in the opinion of management for a fair statement of results for the interim periods presented.


The results of operations for the six months ended June 30, 2012 are not necessarily indicative of the results to be expected for the full year.


Certain minor reclassifications in prior period amounts have been made to conform to the current period presentation.


NOTE 2 – GOING CONCERN

The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, in addition to a working capital deficiency at June 30, 2012, the Company has incurred negative cash flow from operations and significant losses, which have substantially increased its operating deficit at June 30, 2012.   These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The Company’s ability to continue as a going concern will be dependent upon economic developments and the success of management's plans as set forth below, which cannot be assured.  The accompanying financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.  Management and board members are continuing to discuss other alternative financing options, but no definitive proposals or agreements have been reached.


The foregoing notwithstanding, management does not believe the Company currently has sufficient capital to sustain its planned business activities for the next twelve months following the issuance of these financial statements. Accordingly, while management has historically been successful generating sufficient funds to sustain operations, there is no assurance that they will continue to do so. Nevertheless, the Company will seek additional capital to sustain its operations, either through additional private placements of common stock or loans, possibly unsecured, until such time as its operations are self-sustaining.  These funds will be required to continue the Company’s efforts to generate sales of its products and to provide sufficient working capital to meet the expected sales demand.


NOTE 3 –SIGNIFICANT TRANSACTIONS


During the six months ended June 30, 2012, the Company received cash advances from two executive officers of $13,700 and $12,000, respectively with no specific repayment terms. And two officers paid expenses on behalf of the Company for an amount of $9,613 and $5,297, respectively. In addition, the Company repaid $8,703 to one officer by issuing common stock of 290,099 shares and repaid $22,927 to another officer in cash. Furthermore, the Company received $25,000 from issuance of 1,000,000 shares of common stock during February, 2012.


Due to the fair value of the common shares being less than the carrying value of the related payables, the Company recognized a gain on settlement of payables of $2,365 during the six months ended June 30, 2012.  An additional gain of $5,000 was generated by writing off payables due to the expiration of the statute of limitations.







6



NANO MASK, INC.

Notes to the Financial Statements (Unaudited)

For the Six Months Ended June 30, 2012




The following table summarizes the common stock issued during the six months ended June 30, 2012:



Summary of Stock Issuances during the Six Months ended June 30, 2012

Settlement of Liabilities

 

Settlement of Advances-Related Party

 

Compensation

Cash Proceeds

Common Shares

 

Fair Value

 

Common Shares

 

Fair Value

 

Common Shares

 

Fair Value

Common

Shares

Fair Value

5,085,671

 

$ 169,863

 

290,099

 

$  8,703

 

2,064,442

 

$92,900

1,000,000

$ 25,000



NOTE 4 – SUBSEQUENT EVENTS


Subsequent to June 30, 2012, the Company received cash advances from two executive officers of $13,200.



NOTE 5 – CONTINGENCIES


On March 5 2012, the Company received a complaint from a certain attorney seeking collection of his invoices in the amount of $167,167, plus interest and litigation expenses. The Company does not believe the claim has any merit and has submitted a motion for dismissal. At this point, the Company is awaiting the claimant’s amendment to his claim.


On or about May 8, 2012, the Company received a complaint from a certain former employee seeking collection of his charges as a distributor and as an employee in the amount of $409,525, plus interest and litigation expenses. The Company believes the likelihood of loss in this case is remote and intends to offset for certain expenditures made by the Company caused by employee. The Company has already recognized $37,500 as a liability at June 30, 2012.



7





ITEM 2

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


Cautionary Statement Regarding Forward-looking Statements


This report may contain "forward-looking" statements.  Examples of forward-looking statements include, but are not limited to: (a) projections of revenues, capital expenditures, growth, prospects, dividends, capital structure and other financial matters; (b) statements of plans and objectives of our management or Board of Directors; (c) statements of our future economic performance; (d) statements of assumptions underlying other statements and statements about us and our business relating to the future; and (e) any statements using the words "anticipate," "expect," "may," "project," "intend" or similar expressions.


Overview


The Company is in the business of producing environmental masks and filters for medical devices that are designed to reduce the possibility of transmission of contagious diseases.  


Since its inception, the Company has been involved in the development of its technology.  Through June 30, 2012, revenues have not been adequate to cover operating expenses and thus, the Company has reported a loss in each of its years of existence.  Through June 30, 2012, the Company has funded itself by way of a series of private equity placements and had offset its accumulated deficit in this manner.


Results of Operations for the Three Months Ended June 30, 2012 compared with 2011


Revenues:  During the three months ended June 30, 2012, there were revenues of approximately $81,000 derived from sale of Sheets (84%) and Nano Zymes (16%). During the three months ended June 30, 2011, there were revenues of approximately $25,500 derived from sales of Lab Coats (60%), Vira Masks (21%), Nano Zymes (16%) and other (3%).


Cost of Sales:  Cost of sales as a percentage of sales approximated 79% for the three months ended June 30, 2012 compared with 66% in the similar period of 2011. This higher percentage in the last three months is attributable to lower margins for our product sales in this period.


Operating Expenses: During the three months ended June 30, 2012 the Company’s general and administrative expenses declined by approximately $96,000 or 37%, compared to the three months ended June 30, 2011, primarily due to a significant reduction in auditing fees ($120,000) offset by increases in salaries ($27,000). The significant components of our operating expenses include salaries and wages, consulting and other professional services, accounting, audit and legal fees, product and liability insurance and travel.


Research and development: Research and development (R&D) expenditures have become inconsequential in both 2012 and 2011 as management devotes its limited resources to the products that it has recently developed through third-party sources. If resources are available in the future, the Company intends to bring additional products to market, assuming those products are still viable at the time the resources are available. The significant components of the Company’s research and development costs ordinarily include prototype development and materials, governmental filings and laboratory testing.


Results of Operations for the Six Months Ended June 30, 2012 compared with 2011


Revenues: During the six months ended June 30, 2012, revenues of approximately $300,000 reflect the following products: Sheets (96%) and Nano Zyme products (4%). Revenues of approximately $25,700 in 2011 for the same period reflect the following products: Lab Coats (60%), Vira Masks (21%), Nano Zymes (16%) and other (3%).


Cost of Sales:  During the six months ended June 30, 2012, the cost of sales percentage to sales of 68% is largely similar to the 66% for the six months ended June 30, 2011.



8






Operating Expenses: During the six months ended June 30, 2012, the Company realized reduced general and administrative expenses of approximately $29,000 or approximately 7% compared to the six months ended June 30, 2011, primarily attributable to reduced auditing fees ($106,000), offset by salaries and director fees ($58,000) and sales-related expenses ($21,000).  


Research and development: Research and development (R&D) expenditures have become inconsequential in both 2012 and 2011 as management devotes its limited resources to the products that it has recently developed through third-party sources. If resources are available in the future, the Company intends to bring additional products to market, assuming those products are still viable at the time the resources are available. The significant components of the Company’s research and development costs ordinarily include prototype development and materials, governmental filings and laboratory testing.


Liquidity and Capital Resources


             The Company has not been able to generate sufficient net cash inflows from operations to sustain its business efforts and accommodate its growth plans. During the six months ended June 30, 2012, the Company received cash advances from two executive officers of $13,700 and $12,000, respectively with no specific repayment terms. And two officers paid expenses on behalf of the Company for an amount of $9,613 and $5,297, respectively. In addition, the Company repaid $8,703 to one officer by issuing common stock of 290,099 shares and repaid $22,927 to another officer in cash. During the six months in 2011, the company received cash advances from two officers for the amount of $56,500 and $2,000. The company repaid $2,000 to one officer. Also, during 2012, the Company received $25,000 in cash from issuance of 1,000,000 shares of common stock. Management and board members are continuing to discuss other alternative financing options, but no definitive proposals or agreements have been reached.


Beginning in the third quarter of 2008, the United States has been experiencing a severe and widespread recession accompanied by instability in the financial markets and reduced credit availability which are likely to continue to have far reaching effects on economic activity in the country for an indeterminate period. The effects and probable duration of these conditions and related risks and uncertainties on the Company's ability to obtain financing, success in its marketing efforts and ultimately, profitable operations and positive cash flows, cannot be estimated at this time.


             The Company does not believe, however, that it currently has sufficient capital to sustain its business efforts for the next twelve months.  Accordingly, the Company will need to raise additional capital in the near future to sustain operations.

  

              Accordingly, for these and other reasons, there is significant uncertainty regarding the Company’s future, and the Company’s auditors expressed substantial doubt as to the Company’s ability to continue as a going concern in their report on the Company’s 2011 audited financial statements.

                            

Impact of Inflation


At this time, the Company does not anticipate that inflation will have a material impact on its current or future operations.


Critical Accounting Policies and Estimates


Except with regard to the estimated useful lives of patents and acquired technology, the net realizable value of the Company’s inventory due to shelf-life issues and design, the allowance for bad debts on accounts receivable, and the effective provision of a 100% deferred income tax asset valuation allowance, the Company does not employ any critical accounting policies or estimates that are either selected from among available alternatives or require the exercise of significant management judgment to apply or that if changed are likely to materially affect future periods.  


Management reviews the carrying value of the technology assets annually based on its current marketing



9





activities, plans and expectations, and the perceived effects of competitive factors and possible obsolescence, whether any write-downs should be taken or whether the estimated useful lives should be shortened.  


Management also reviews the carrying value of its inventory periodically for evidence of declines in estimated fair value and considers, based on its current marketing activities, plans and expectations, and the perceived effects of competitive factors and possible obsolescence due to shelf-life issues on the environmental filters, whether any write-downs should be taken.


Management also reviews the collectability of outstanding receivables based upon historical collection history from each customer, the age of the receivables, and the customers wherewithal to pay the outstanding balance, and records an estimated allowance for bad debts sufficient to cover any potential losses to be incurred for non-collections.


The carrying values of prepaid expenses, accounts payable, accrued expenses and short term notes payable generally approximate the respective fair values of these instruments due to their current nature.


Recent Accounting Pronouncements


While there have been Financial Accounting Standards Board (FASB) pronouncements made effective subsequent to the issuance of these financial statements, none would have required restatement of the financial statements herein nor have they had any significant effect on future financial statements of the Company.


ITEM 3

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK


Smaller reporting companies are not required to provide the information required by this item.


ITEM 4

CONTROLS AND PROCEDURES


We maintain a system of disclosure controls and procedures that are designed for the purpose of ensuring that information required to be disclosed in our SEC reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Chief Executive Officer and the Principal Accounting Officer, as appropriate to allow timely decisions regarding required disclosures.

 Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 under the Securities Exchange Act of 1934, as of June 30, 2012, the end of the period covered by this quarterly report, we have carried out an evaluation of the effectiveness of the design and operation of our company’s disclosure controls and procedures. This evaluation was carried out under the supervision and with the participation of our company’s management, including our company’s Chief Executive Officer and Chief Financial Officer. Based upon that evaluation, our company’s Chief Executive Officer and Chief Financial Officer concluded that our company’s disclosure controls and procedures are ineffective as at the end of the period covered by this report.

There have been no changes in our internal controls over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect our internal controls over financial reporting. 



10





PART II


OTHER INFORMATION


ITEM 1 - LEGAL PROCEEDINGS


On March 5 2012, the Company received a complaint from a certain attorney seeking collection of his invoices in the amount of $167,167, plus interest and litigation expenses. The Company does not believe the claim has any merit and has submitted a motion for dismissal. At this point, the Company is awaiting the claimant’s amendment to his claim.  


On or about May 8, 2012, the Company received a complaint from a certain former employee seeking collection of his charges as a distributor and as an employee in the amount of $409,525, plus interest and litigation expenses. The Company believes the likelihood of loss in this case is remote and intends to offset for certain expenditures made by the Company caused by employee. The Company has already recognized $37,500 as a liability at June 30, 2012.



ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS


During the month ended February 28, 2012, 1,000,000 shares of common stock were issued in a private placement to two individual investors for $25,000 in cash.


These shares were issued in reliance on the exemption from registration and prospectus delivery requirements of the Act set forth in Section 3(b) and/or Section 4(2) of the Securities Act and the regulations promulgated hereunder.



11





ITEM 3 - DEFAULTS BY THE COMPANY ON ITS SENIOR SECURITIES

None.


ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.


ITEM 5 - OTHER INFORMATION

None.


ITEM 6 - EXHIBITS


EXHIBIT NO.

DESCRIPTION

 

 

31

CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002.

31

CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002.

32

CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002.

32

CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002.



SIGNATURES


In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


NANO MASK, INC.


August 14, 2012

 /s/ Edward Suydam

Edward Suydam, Chief Executive Officer


August 14, 2012

 /s/ Michael J. Marx

Michael J. Marx, Chief Financial Officer



12